These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26332546)

  • 21. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.
    Tefferi A; Wassie EA; Guglielmelli P; Gangat N; Belachew AA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Pacilli A; Vannucchi AM; Passamonti F
    Am J Hematol; 2014 Aug; 89(8):E121-4. PubMed ID: 24753125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Essential thrombocythemia: scientific advances and current practice.
    Tefferi A
    Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.
    Wang X; Hu CS; Petersen B; Qiu J; Ye F; Houldsworth J; Eng K; Huang F; Hoffman R
    Blood Adv; 2018 Sep; 2(18):2378-2388. PubMed ID: 30242099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
    Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
    Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
    [No Abstract]   [Full Text] [Related]  

  • 31. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.
    Henry L; Carillo S; Jourdan E; Arnaud A; Brun S; Lavabre-Bertrand T
    Am J Hematol; 2007 Jun; 82(6):500-1. PubMed ID: 17301972
    [No Abstract]   [Full Text] [Related]  

  • 33. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
    Lambert JR; Gale RE; Linch DC
    Br J Haematol; 2009 Apr; 145(1):128-30. PubMed ID: 19222478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.
    González-Sales M; Lennox AL; Huang F; Pamulapati C; Wan Y; Sun L; Berry T; Kelly Behrs M; Feller F; Morcos PN
    CPT Pharmacometrics Syst Pharmacol; 2024 Jul; 13(7):1264-1277. PubMed ID: 38771074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
    Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
    Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
    Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
    Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
    Mascarenhas J; Komrokji RS; Palandri F; Martino B; Niederwieser D; Reiter A; Scott BL; Baer MR; Hoffman R; Odenike O; Vannucchi AM; Bussolari J; Zhu E; Rose E; Sherman L; Dougherty S; Sun L; Huang F; Wan Y; Feller FM; Rizo A; Kiladjian JJ
    J Clin Oncol; 2021 Sep; 39(26):2881-2892. PubMed ID: 34138638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blast phase of essential thrombocythemia: A single center study.
    Passamonti F; Rumi E; Arcaini L; Elena C; Castagnola C; Zappasodi P; Bernasconi P; Pietra D; Pascutto C; Cazzola M; Lazzarino M
    Am J Hematol; 2009 Oct; 84(10):641-4. PubMed ID: 19691103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.